Changeflow GovPing Pharma & Drug Safety Novel Anti-Sugar Chain Antibody and Use Thereof
Routine Notice Added Final

Novel Anti-Sugar Chain Antibody and Use Thereof

Favicon for changeflow.com EPO Patent Bulletin - Biotech (C12N)
Published
Detected
Email

Summary

The European Patent Office published patent EP4227413A1 for National University Corporation Chiba University, covering a novel anti-sugar chain antibody and its therapeutic applications. The patent addresses immunology treatments including A61P 37/00 and A61P 43/00. The publication designates multiple European states including DE, FR, GB, IT, NL, ES, and others. Inventors are Kawashima Hiroto and Matsumura Ryuji.

What changed

The EPO published patent application EP4227413A1 for Chiba University covering a novel anti-sugar chain antibody and its use. The invention falls under IPC classifications C07K 16/28 (immunoglobulins), C12N 15/13 (vector constructs), and C12P 21/08 (production methods), with therapeutic applications in immunological disorders.

Patent publications are informational records of granted intellectual property rights. Pharmaceutical companies developing antibody therapeutics should conduct freedom-to-operate analyses before commercializing similar products in designated EU states. No immediate compliance actions are required.

Archived snapshot

Apr 2, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

NOVEL ANTI-SUGAR CHAIN ANTIBODY AND USE THEREOF

Publication EP4227413A1 Kind: A1 Mar 25, 2026

Applicants

National University Corporation Chiba University

Inventors

KAWASHIMA, Hiroto, MATSUMURA, Ryuji

IPC Classifications

C12N 15/13 20060101AFI20240917BHEP A61P 37/00 20060101ALI20240917BHEP A61P 43/00 20060101ALI20240917BHEP C07K 16/28 20060101ALI20240917BHEP C07K 16/46 20060101ALI20240917BHEP C12N 1/15 20060101ALI20240917BHEP C12N 1/19 20060101ALI20240917BHEP C12N 1/21 20060101ALI20240917BHEP C12N 5/10 20060101ALI20240917BHEP C12P 21/08 20060101ALI20240917BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
EPO
Published
March 25th, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP4227413A1

Who this affects

Applies to
Pharmaceutical companies Healthcare providers
Industry sector
3254.1 Biotechnology 3254 Pharmaceutical Manufacturing
Activity scope
Biotech Patent
Geographic scope
European Union EU

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Topics
Intellectual Property

Get alerts for this source

We'll email you when EPO Patent Bulletin - Biotech (C12N) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.